NO20020214L - Substituerte oksoazaheterocyklylforbindelser - Google Patents

Substituerte oksoazaheterocyklylforbindelser

Info

Publication number
NO20020214L
NO20020214L NO20020214A NO20020214A NO20020214L NO 20020214 L NO20020214 L NO 20020214L NO 20020214 A NO20020214 A NO 20020214A NO 20020214 A NO20020214 A NO 20020214A NO 20020214 L NO20020214 L NO 20020214L
Authority
NO
Norway
Prior art keywords
compounds
factor
substituted
oxoazaheterocyclyl compounds
oxoazaheterocyclyl
Prior art date
Application number
NO20020214A
Other languages
English (en)
Other versions
NO20020214D0 (no
Inventor
William R Ewing
Michael R Becker
Yong Mi Choi-Sledeski
Heinz W Pauls
Wei He
Stephen M Condon
Roderick S Davis
Barbara A Hanney
Alfred P Spada
Christopher J Burns
John Z Jiang
Aiwen Li
Michael R Myers
Wan F Lau
Gregory B Poli
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of NO20020214D0 publication Critical patent/NO20020214D0/no
Publication of NO20020214L publication Critical patent/NO20020214L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20020214A 1999-07-28 2002-01-15 Substituerte oksoazaheterocyklylforbindelser NO20020214L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36319699A 1999-07-28 1999-07-28
PCT/IB2000/001156 WO2001007436A2 (en) 1999-07-28 2000-07-26 Substituted oxoazaheterocyclyl compounds

Publications (2)

Publication Number Publication Date
NO20020214D0 NO20020214D0 (no) 2002-01-15
NO20020214L true NO20020214L (no) 2002-04-02

Family

ID=23429232

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020214A NO20020214L (no) 1999-07-28 2002-01-15 Substituerte oksoazaheterocyklylforbindelser

Country Status (25)

Country Link
EP (1) EP1208097B1 (no)
JP (1) JP4829449B2 (no)
KR (1) KR20020087041A (no)
CN (1) CN1420882A (no)
AT (1) ATE423113T1 (no)
AU (1) AU773227B2 (no)
BG (1) BG106340A (no)
BR (1) BR0013179A (no)
CA (1) CA2382755A1 (no)
CR (1) CR6563A (no)
CZ (1) CZ2002323A3 (no)
DE (1) DE60041584D1 (no)
EE (1) EE200200045A (no)
HK (1) HK1054227A1 (no)
HR (1) HRP20020076A2 (no)
HU (1) HUP0203375A3 (no)
IL (2) IL147495A0 (no)
MX (1) MXPA02000888A (no)
NO (1) NO20020214L (no)
PL (1) PL354998A1 (no)
RU (1) RU2002105011A (no)
SK (1) SK1182002A3 (no)
TR (1) TR200200225T2 (no)
WO (1) WO2001007436A2 (no)
ZA (1) ZA200200543B (no)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12323A (en) 2000-03-21 2006-05-15 Smithkline Beecham Corp Protease inhibitors.
AU2002211280A1 (en) * 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Piperazin-2-one amides as inhibitors of factor Xa
PL364279A1 (en) * 2001-02-02 2004-12-13 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
DE60209736T2 (de) 2001-07-02 2006-11-02 Astrazeneca Ab Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AU2007229363B2 (en) * 2001-08-24 2009-06-04 University Of South Florida Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and the Methods of Treatment
DE60234354D1 (de) 2001-08-24 2009-12-24 Univ Yale Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
EP1483241A4 (en) 2002-03-08 2006-12-13 Bristol Myers Squibb Co CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
WO2003087089A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
EP1505067A4 (en) 2002-04-25 2006-06-21 Teijin Ltd 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES WITH CCR3 ANTAGONISM
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
WO2004032930A1 (ja) * 2002-10-11 2004-04-22 Kowa Co., Ltd. 癌の処置方法
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
CA2508165C (en) 2002-12-06 2014-05-06 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US8729107B2 (en) 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
CN100516040C (zh) 2003-03-07 2009-07-22 安斯泰来制药有限公司 具有2,6-二取代苯乙烯基的含氮杂环衍生物
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
WO2006019497A2 (en) 2004-06-17 2006-02-23 Neurocrine Biosciences, Inc. Sleep-inducing compounds and methods related thereto
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
WO2007008146A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2007008144A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
CA2615650A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
JP5147401B2 (ja) * 2005-09-06 2013-02-20 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
WO2007038215A1 (en) 2005-09-22 2007-04-05 Incyte Corporation Tetracyclic inhibitors of janus kinases
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
US7622496B2 (en) 2005-12-23 2009-11-24 Zealand Pharma A/S Modified lysine-mimetic compounds
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
US7709496B2 (en) 2006-04-06 2010-05-04 Glaxo Group Limited Antibacterial agents
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8999984B2 (en) * 2006-05-26 2015-04-07 University Of Louisville Research Foundation, Inc. Macrophage migration inhibitory factor antagonists and methods of using same
EP1882688A1 (en) 2006-07-25 2008-01-30 EPFL Ecole Polytechnique Fédérale de Lausanne Labelling of fusion proteins with synthetic probes
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
ES2558856T3 (es) 2006-12-21 2016-02-09 Zealand Pharma A/S Síntesis de compuestos de pirrolidina
EA019103B1 (ru) * 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2011038234A2 (en) 2009-09-24 2011-03-31 University Of Louisville Research Foundation, Inc. Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions
WO2011146824A1 (en) 2010-05-20 2011-11-24 University Of Louisville Research Foundation, Inc. Methods and compositions for modulating ocular damage
KR101251282B1 (ko) 2010-10-18 2013-04-10 서울대학교산학협력단 프로스타글란딘 합성을 억제하는 설폰아미드 유도체 및 이를 포함하는 약학적 조성물
WO2012062044A1 (zh) * 2010-11-12 2012-05-18 Yao Xuebiao 动点马达蛋白cenp-e小分子抑制剂syntelin及其应用
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
PL395470A1 (pl) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
CN111393434B (zh) 2014-04-30 2022-11-04 哥伦比亚大学董事会 取代的4-苯基哌啶及其制备和用途
JP6625610B2 (ja) 2014-07-31 2019-12-25 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ピラゾールの調製方法
CN104610259B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104557928B (zh) * 2015-02-14 2016-08-24 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途
CN104610258B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途
CN104610257B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类含酰胺结构的FXa抑制剂、制备方法及其用途
CN104672235B (zh) * 2015-02-14 2016-02-17 佛山市赛维斯医药科技有限公司 一类含双酰胺基和烷氧苯基结构的FXa抑制剂及其用途
CN104592227B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类含酰胺和卤代苯结构的FXa抑制剂、制备方法及其用途
CN104672236B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途
CN104650081B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 凝血因子Xa抑制剂、制备方法及其用途
CN104610260B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104557930B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构凝血因子Xa抑制剂及其用途
CN104557929B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途
CN104557927B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构的凝血因子Xa抑制剂及其用途
CN104650082B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类凝血因子Xa抑制剂、制备方法及其用途
CN107592859A (zh) 2015-05-11 2018-01-16 巴斯夫欧洲公司 制备4‑氨基哒嗪类的方法
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
EP3313836B1 (en) 2015-06-26 2020-11-11 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
JP6787913B2 (ja) * 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
WO2018082964A1 (en) 2016-11-04 2018-05-11 Basf Se Process for the production of pyridazinyl-amides in a one-pot synthesis
WO2018194181A1 (en) 2017-04-18 2018-10-25 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
ES2870106T3 (es) 2017-05-05 2021-10-26 Zealand Pharma As Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
CN110054619A (zh) * 2018-01-18 2019-07-26 西北农林科技大学 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂
MX2020010657A (es) 2018-04-10 2020-10-28 Bayer Ag Derivados de oxadiazolina.
CN109991355B (zh) * 2019-04-12 2021-05-11 中国烟草总公司郑州烟草研究院 一种鉴定动物体内nab代谢产物的方法和评价nab在动物体内暴露风险的方法
WO2022228387A1 (en) * 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK102495A3 (en) * 1993-02-22 1997-01-08 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical agents containing them
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
AU747531B2 (en) * 1997-04-14 2002-05-16 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
AU1692399A (en) * 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Aromatic compounds having cyclic amino or salts thereof
YU47600A (sh) * 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
JP2000204081A (ja) * 1998-02-05 2000-07-25 Takeda Chem Ind Ltd スルホンアミド誘導体、その製造法及び用途
CN1290254A (zh) * 1998-02-05 2001-04-04 武田药品工业株式会社 氨磺酰衍生物及其制备和用途
JP2003529531A (ja) * 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換オキソアザへテロシクリルＸａ因子阻害剤

Also Published As

Publication number Publication date
SK1182002A3 (en) 2002-11-06
JP2003508353A (ja) 2003-03-04
NO20020214D0 (no) 2002-01-15
CR6563A (es) 2008-11-25
DE60041584D1 (de) 2009-04-02
ATE423113T1 (de) 2009-03-15
RU2002105011A (ru) 2004-01-20
CA2382755A1 (en) 2001-02-01
BG106340A (en) 2002-10-31
PL354998A1 (en) 2004-03-22
MXPA02000888A (es) 2002-07-30
AU6462800A (en) 2001-02-13
JP4829449B2 (ja) 2011-12-07
WO2001007436A3 (en) 2001-08-23
TR200200225T2 (tr) 2002-06-21
HUP0203375A2 (hu) 2002-12-28
AU773227B2 (en) 2004-05-20
CZ2002323A3 (cs) 2002-05-15
HRP20020076A2 (en) 2003-12-31
HUP0203375A3 (en) 2005-03-29
KR20020087041A (ko) 2002-11-21
WO2001007436A2 (en) 2001-02-01
HK1054227A1 (zh) 2003-11-21
ZA200200543B (en) 2003-08-27
BR0013179A (pt) 2002-04-02
EE200200045A (et) 2003-06-16
IL147495A0 (en) 2002-08-14
CN1420882A (zh) 2003-05-28
EP1208097B1 (en) 2009-02-18
IL147495A (en) 2007-07-24
EP1208097A2 (en) 2002-05-29

Similar Documents

Publication Publication Date Title
NO20020214D0 (no) Substituerte oksozaheterocyklylforbindelser
AP2000001889A0 (en) Substituted ozoazaheterocyclyl factor Xa inhibitors.
DE69830504D1 (de) Antithrombotische mitteln
DE69919212D1 (de) Aromatische amiden
DE60130771D1 (de) Substituierte heterocyclische amide
ATE306261T1 (de) Antithrombosemittel
DE69931393D1 (de) Antithrombotische amide
HK1053831A1 (zh) 作为治疗药物的激酶抑制剂
DK1140918T3 (da) Thrombininhibitorer
MXPA04001323A (es) Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso.
CY1107634T1 (el) Φαρμακευτικη συνθεση
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BR0313969A (pt) Inibidores de oxitocina
SE9901077D0 (sv) Novel use
ATE411287T1 (de) Neue metallproteinaseinhibitoren
ATE453389T1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
DE60114640D1 (en) Antithrombosemittel
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
MXPA03002493A (es) Proceso eficiente para preparacion de un inhibidor del factor xa.
ATE372982T1 (de) 2-(3-sulfonylamino-2-oxopyrrolidin-1- yl)propanamide als factor xa inhibitoren
EA200401099A1 (ru) Производные гетероциклического амида
ATE382607T1 (de) Antitrombotische aether
NO981089L (no) Epoksy-azetidinoner, fremstilling og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application